Part 1. Formation of the stratum-specific effect estimates in the two-stage meta-analysis. Table S1 . Primary values derived from the original articles and effect estimates used in the metaanalysis: all non-accidental causes. Table S2 . Primary values derived from the original articles and effect estimates used in the metaanalysis: cardiovascular diseases. Table S3 . Primary values derived from the original articles and effect estimates used in the metaanalysis: respiratory diseases. Table S4 . Primary values derived from the original articles and effect estimates used in the metaanalysis: males, all non-accidental causes. Table S5 . Primary values derived from the original articles and effect estimates used in the metaanalysis: females, all non-accidental causes.
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Part 1. Formation of the stratum-specific effect estimates in the two-stage meta-analysis. Table S1 . Primary values derived from the original articles and effect estimates used in the metaanalysis: all non-accidental causes. Table S2 . Primary values derived from the original articles and effect estimates used in the metaanalysis: cardiovascular diseases. Table S3 . Primary values derived from the original articles and effect estimates used in the metaanalysis: respiratory diseases. Table S4 . Primary values derived from the original articles and effect estimates used in the metaanalysis: males, all non-accidental causes. Table S5 . Primary values derived from the original articles and effect estimates used in the metaanalysis: females, all non-accidental causes. Table S6 . Primary values derived from the original articles and effect estimates used in the metaanalysis: ages 0-64, all non-accidental causes. Table S7 . Primary values derived from the original articles and effect estimates used in the metaanalysis: ages 65+, all non-accidental causes. Table S8 . Characteristics of studies included in the systematic review but not in a group, complementary information. Table S9 . Estimation of mortality in the index periods (cold spells) and reference periods for the studies in the meta-analyses. Part 1. Formation of the stratum-specific effect estimates in the two-stage meta-analysis. Xie et al. (2013) provided effect estimates in the age strata 0-64, 65-74, and ≥75 without presenting an estimate for ages ≥65. We used the effect estimates for the age groups 65-74 and ≥75 to calculate a summary-effect estimate for the age group ≥65 using the two-stage metaanalysis (Table S7 ). The three effect estimates for Xie at al. (2013) present in figures (2-4), and tables (S1-S6) represent cold spells in different cities. Ma et al. (2012) provided effect estimates for multiple age groups (0-4, 5-44, 45-64, and ≥65) without presenting an estimate for the age group 0-64. We used the effect estimates for the age groups 0-4, 5-44, and 45-64 to calculate a summary-effect estimate for age group 0-64 using the two-stage meta-analysis (Table S6) . Revich and Shaposhnikov (2010) provided effect estimates in two age strata, 30-64 and ≥65. We used the effect estimates for the age groups 30-64 and ≥65 to calculate a summary-effect estimate for the whole age range using the two-stage meta-analysis (Tables S1 and S2 ). The original estimate for ages 30-64 was deemed representative of ages 0-64 and used in the metaanalyses as such (Table S6) . It should be noted that Revich and Shaposhnikov (2010) reported that the number of deaths under 30 years was too small to analyze. Effect estimates were also provided for diagnoses that did not cover the whole range of cardiovascular (ICD-10 I00-I99) diseases. We used the effect estimates for diagnoses of ischemic heart disease and cerebrovascular diseases to calculate a summary-effect estimate for cardiovascular diseases using the two-stage meta-analysis (Table S2) . Revich and Shaposhnikov (2010) reported that based on absolute numbers of deaths, these two were the most significant causes among cardiovascular deaths. Kyselý et al. (2009) provided effect estimates for cardiovascular mortality stratified by sex, without presenting an estimate for both sexes combined. We used the effect estimates for males (all ages) and females (all ages) to calculate a summary-effect estimate for cardiovascular mortality using the two-stage meta-analysis (Table S2) . It should be noted that Kyselý et al. (2009) did not include age groups 0-24 in their analyses because of the very small sample size of this group in their cardiovascular mortality data. Revich and Shaposhnikov (2008) provided effect estimates only in the age stratum of ≥75 years.
The effect estimates in the age stratum ≥75 were deemed representative of the age stratum ≥65 years but not of the whole age range 0 to 65 and over, and were used in the meta-analyses accordingly. The two effect estimates for Revich and Shaposhnikov (2008) present in figures and tables represent 2 different cold spells (Table S7) . Huynen et al. (2001) provided effect estimates for independent cold spells occurring on different years (Tables S1-S3 ). These observations were deemed independent and used in the metaanalyses accordingly. Suitable age-stratified effect estimates were available for one year only (Tables S6 and S7) . Borst et al. (1997) provided effect estimates for age strata <65, 65-74, 75-84, 85-94, and >95 without presenting an effect estimate for ages ≥65. We used the effect estimates for the age groups 65-74, 75-84, 85-94 , and >95 to calculate a summary-effect estimate for age group ≥65 using the two-stage meta-analysis (Table SS7) . Borst et al. (1997) provided effect estimates for diagnoses that did not cover the whole range of cardiovascular (ICD-10 I00-I99) or respiratory (J00-J99) diseases. We used the effect estimates of cardiac disease and cerebrovascular accident (Table S2 ) to calculate a summary-effect estimate for cardiovascular diseases using the two stage meta-analysis. We used COPD to represent respiratory diseases (Table S3) . Abbreviations: Rate Ratio, mortality-rate ratio, derived from the original article; Secondary-Rate Ratio, study-specific effect estimate used in the meta-analysis; 95% CI, 95% confidence interval; "?" indicates that more than one value contributed to the study-specific effect estimate presented below the arrow. Definitions: Effect Type = cumulative if the effect estimate presented in the study was calculated for a time period; Effect Type = daily if the effect was estimated per one day; Lag Days, the number of days used in the conversion of a cumulative measure to a daily measure. Abbreviations: Rate Ratio, mortality-rate ratio, derived from the original article; Secondary-Rate Ratio, study-specific effect estimate used in the meta-analysis; 95% CI, 95% confidence interval; "?" indicates that more than one value contributed to the study-specific effect estimate presented below the arrow; CVD, cardiovascular diseases; IHD, ischemic heart disease; Cerebro, cerebrovascular disease or cerebrovascular accident; CD, cardiac disease. Definitions: Effect Type = cumulative if the effect estimate presented in the study was calculated for a time period; Effect Type = daily if the effect was estimated per one day; Lag Days, the number of days used in the conversion of a cumulative measure to a daily measure. Abbreviations: Rate Ratio, mortality-rate ratio, derived from the original article; Secondary-Rate Ratio, study-specific effect estimate used in the meta-analysis; 95% CI, 95% confidence interval; "?" indicates that more than one value contributed to the study-specific effect estimate presented below the arrow; Resp, respiratory diseases; COPD, chronic obstructive pulmonary disease. Definitions: Effect Type = cumulative if the effect estimate presented in the study was calculated for a time period; Effect Type = daily if the effect was estimated per one day; Lag Days, the number of days used in the conversion of a cumulative measure to a daily measure. Abbreviations: Rate Ratio, mortality-rate ratio, derived from the original article; Secondary-Rate Ratio, study-specific effect estimate used in the meta-analysis; 95% CI, 95% confidence interval; "?" indicates that more than one value contributed to the study-specific effect estimate presented below the arrow. Definitions: Effect Type = cumulative if the effect estimate presented in the study was calculated for a time period; Effect Type = daily if the effect was estimated per one day; Lag Days, the number of days used in the conversion of a cumulative measure to a daily measure. Abbreviations: Rate Ratio, mortality-rate ratio, derived from the original article; Secondary-Rate Ratio, study-specific effect estimate used in the meta-analysis; 95% CI, 95% confidence interval; "?" indicates that more than one value contributed to the study-specific effect estimate presented below the arrow. Definitions: Effect Type = cumulative if the effect estimate presented in the study was calculated for a time period; Effect Type = daily if the effect was estimated per one day; Lag Days, the number of days used in the conversion of a cumulative measure to a daily measure. Abbreviations: Rate Ratio, mortality-rate ratio, derived from the original article; Secondary-Rate Ratio, study-specific effect estimate used in the meta-analysis; 95% CI, 95% confidence interval; "?" indicates that more than one value contributed to the study-specific effect estimate presented below the arrow. Definitions: Effect Type = cumulative if the effect estimate presented in the study was calculated for a time period; Effect Type = daily if the effect was estimated per one day; Lag Days, the number of days used in the conversion of a cumulative measure to a daily measure. Abbreviations: Rate Ratio, mortality-rate ratio, derived from the original article; Summary-Rate Ratio, study-specific effect estimate used in the meta-analysis; 95% CI, 95% confidence interval; "?" indicates that more than one value contributed to the study-specific effect estimate presented below the arrow. Definitions: Effect Type = cumulative if the effect estimate presented in the study was calculated for a time period; Effect Type = daily if the effect was estimated per one day; Lag Days, the number of days used in the conversion of a cumulative measure to a daily measure. Expected M calculated using same calendar days during the other years of the study period; a proxy for expected background mortality Huynen et al. 2001 Applying absolute T threshold to all study days identifies winter cold spells; rarity does not depend on the duration of the study period Observed M during ≥ 9 days with daily Tmin ≤ -5°C, of which ≥ 6 days with daily Tmin ≤ -10°C
Annual cycle-based, Counterfactual inference Expected M calculated using a 31-day moving average of daily M for cold spell days of the 2 preceding years combined Borst et al. 1997 A proxy for winter cold spells; rarity does not depend on the duration of the study period or the duration of the cold spell Observed M during all 7 day-periods with average of weekly Tmax < 5°C
Period of lowest mortality, Counterfactual inference Observed M during all 7 day-periods with average of weekly Tmax 15.0-19.9C; optimum temperature range defined by lowest mortality in 6 temperature strata Abbreviations: M, mortality; Tmin, daily minimum temperature; Tave, daily average temperature; DOW, day of the week; Tmean, daily mean temperature; df, degrees of freedom; Tmax, daily maximum temperature. Definitions: Annual cycle-based, selection of the reference period takes into account potential annual cycles by using the same calendar days as the exposure from other years; Seasonally standardized, selection of the reference period takes into account potential seasonal variation by using near-term days of the same year or other years; Annually standardized, selection of the reference period takes into account potential differences between years by using days of the same year as the exposure; Weekly standardized, selection of the reference period takes into account potential variation by weekday by using same days of the week as the exposure, for the same year or other years; Rarity depends on the duration of the study period, the absolute number of days below a statistically defined percentile becomes greater if the number of days in the frequency distribution is increased. Rarity is still influenced by definition of minimum duration of the event, as it can't be controlled which portion of the individual cold days occur consecutively and which separately.
